The Fight Against Superbugs Heats Up
Boston University School of Law’s Kevin Outterson* looks at how cost-saving measures are contributing to the rise of drug-resistant “superbugs” in the US and the steps that need to be…
Address: 781 Chestnut Ridge Rd, Morgantown, WV 26505,United States of America
Tel: 1-800-RX-MYLAN
Mylan Pharmaceuticals, a subsidiary of Mylan Inc. based in Morgantown, W.Va., is a market leader in researching, developing, manufacturing, marketing and distributing generic pharmaceutical products in a variety of sophisticated dosage forms. Since 1961, Mylan Pharmaceuticals has held a long-standing reputation for quality, integrity and exemplary service and has maintained its commitment to increasing and protecting consumer access to affordable pharmaceuticals.
Mylan Pharmaceuticals has one of the largest product portfolios in the U.S., consisting of more than 200 products. According to IMS Health, one of every 12 prescriptions dispensed in the U.S. is a Mylan product.1 The company pioneered and continues to specialize in groundbreaking delivery technologies and difficult-to-manufacture and -formulate pharmaceuticals that treat diseases ranging from angina to arthritis, depression to diabetes, pain to Parkinson’s disease, and schizophrenia to sleep disorders.
Boston University School of Law’s Kevin Outterson* looks at how cost-saving measures are contributing to the rise of drug-resistant “superbugs” in the US and the steps that need to be…
Monica Weldon, CEO and president of Bridge the Gap – SYNGAP Education and Research Foundation, shares her recent experience at the US Drug Law and Regulation course in Washington, DC…
Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the advancement of cutting edge cell and gene…
The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and…
AstraZeneca’s Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather than finger-pointing, is the only way forward. Discussion…
BioNJ’s president and CEO Debbie Hart reflects on the association’s mission of creating a robust and engaging life sciences ecosystem in New Jersey. Hart also outlines how BioNJ is hoping…
Carla Smith looks at the various cybersecurity risks that exist across the US healthcare continuum and the steps that executive leadership can take to combat this threat. Keeping patient…
The US drug-price watchdog, The Institute for Clinical & Economic Review (ICER) recently issued a “Report on Unsupported Price Increases,” picking a number of innovative medicines that it says have…
Sophia Ononye outlines the history of cannabis as a medicine in the US and, following the first FDA approval of a cannabis-derived drug product in 2018, the highly promising landscape…
The AAM’s Chip Davis tackles the issue of abandonment within US healthcare and proposes three measures to boost competition, thereby lowering drug prices and reducing abandonment rates. Generic and…
Although Boston and California may be more internationally renowned as biotech hubs, New York is fast catching up. Thanks in large part to its strong scientific and business infrastructure and…
Jennifer Hawks Bland of NewYorkBIO, the premier trade association for the life sciences in New York State, discusses the association’s diverse list of members, the services it provides them, and…
See our Cookie Privacy Policy Here
